ADA 2026: The Multi-Agonist and Oral Incretin Readouts, Summarized
ADA 2026 delivered phase 3 data on a triple GLP-1/GIP/glucagon agonist, a dual agonist, CagriSema and two oral agents. Here is the map.
Tagged
clinical-trials
2 notes in this topic
Semaglutide vs. Tirzepatide: Single vs. Dual Agonism in the Literature
What the SUSTAIN, STEP, SURPASS and SURMOUNT programs show about a GLP-1 agonist and a GLP-1/GIP dual agonist, and what the comparison does and does not settle.
All content in the research library is educational and intended for qualified researchers. Products referenced are for laboratory research use only and are not approved for human or veterinary use. Nothing here is medical advice.